A5007658432- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Multiple Myeloma Research and Treatments
- T-cell and B-cell Immunology
- CRISPR and Genetic Engineering
- Cancer, Hypoxia, and Metabolism
- Chronic Lymphocytic Leukemia Research
- Virus-based gene therapy research
- Lymphoma Diagnosis and Treatment
- Cancer Research and Treatments
- Neuroblastoma Research and Treatments
- Protein Degradation and Inhibitors
- MicroRNA in disease regulation
- RNA Research and Splicing
- Hematopoietic Stem Cell Transplantation
- Cancer Cells and Metastasis
- Electrostatic Discharge in Electronics
- Advancements in Semiconductor Devices and Circuit Design
- Peptidase Inhibition and Analysis
University of Ostrava
2020-2023
University Hospital Ostrava
2022-2023
Jagiellonian University
2021
Cellular immunotherapy is becoming a new pillar in cancer treatment after recent striking results different clinical trials with chimeric antigen receptor T cells. However, this innovative therapy not exempt from challenges such as off-tumor toxicity, tumor recurrence heterogeneous tumors, and affordability. To surpass these limitations, we exploit the unique anti-tumor characteristics of natural killer (NK) In study, aimed to obtain clinically relevant number allogeneic NK cells derived...
Multiple myeloma (MM) has witnessed improved patient outcomes through advancements in therapeutic approaches. Notably, allogeneic stem cell transplantation, proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies have contributed to enhanced quality of life. Recently, a promising avenue emerged with chimeric antigen receptor (CAR) T cells targeting B-cell maturation (BCMA), expressed widely on MM cells. To mitigate risks associated allogenic cells, we investigated the...
Multiple myeloma (MM) has witnessed improved patient outcomes through advancements in therapeutic approaches. Notably, allogeneic stem cell transplantation, proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies have contributed to enhanced quality of life. Recently, a promising avenue emerged with chimeric antigen receptor (CAR) T cells targeting B-cell maturation (BCMA), expressed widely on MM cells. To mitigate risks associated allogenic cells, we investigated the...
Myeloma bone disease (MBD) is one of the major complications in multiple myeloma (MM)-the second most frequent hematologic malignancy. It characterized by formation lesions due to local action proliferating MM cells, and date, no effective therapy has been developed. In this study, we propose a novel approach for treatment MBD with combination natural killer cells (NKs) mesenchymal stem (MSCs) within fibrin scaffold, altogether known as FINM. The unique biological properties NKs MSCs, joined...
Abstract Here, we provide evidence that urine progenitor cells (UPCs) might offer a novel therapeutic strategy for treating different types of cancer. We found UPCs have inherent antitumor properties due to cell-cell competition, and described their mechanism action against tumor cell lines. In vitro time-lapse analysis showed the tropic properties, homing various tumor-conditioned mediums. Besides, engineered expression cytotoxic agents (the Tumor Necrosis Factor ligand superfamily member...